Included in the formulation
АТХ:L.02.A.B.03 Gestonoron
Pharmacodynamics:The drug is progestogen.Structurally close to progesterone. At the cellular level inhibits the stimulating effect of testosterone metabolites (androgens) on the development of a number of hormone-dependent tumors in both men and women.
Pharmacokinetics:No data.
Indications:Benign prostatic hyperplasia (if necessary conservative therapy); progressive cancer of the endometrium, the breast.
II.C50.C50 Malignant neoplasm of breast
XIV.N40-N51.N40 Hyperplasia of the prostate
Contraindications:Malignant liver tumors (if they are not caused by metastases of endometrial or breast tumors), including in the anamnesis; liver disease; pregnancy, lactation; herpes pregnant women in the anamnesis.
Carefully:With caution apply for the following concomitant diseases: bronchial asthma, diabetes mellitus, epilepsy, migraine, marked violations of the liver.
Pregnancy and lactation:Contraindicated in pregnancy, lactation, herpes pregnant women in anamnesis.
Dosing and Administration:Intramuscularly slowly - 2 ml (up to 4 ml) once a week. The course - 2-3 months for men, for women - continuous use for a long time.
Side effects:Rarely: gynecomastia, a violation of potency, a decrease in spermatogenesis; in some cases - coughing or coughing, shortness of breath, vascular disorders (during or immediately after injection).
Overdose:No data. Treatment is symptomatic.
Interaction:With the simultaneous use of gestagens with carbamazepine, griseofulvin, phenobarbital, phenytoin, rifampicin, an increase in the clearance of gestagens is possible.
The gestagens can inhibit the metabolism of cyclosporine, which leads to an increase in its concentration in the blood plasma and an increase in toxicity.
Special instructions:If treatment of breast cancer or endometrium develops hypercalcemia, then therapy should be discontinued.